Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials

Lignende værker

• No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
  af: Colhoun, Helen M., et al.
  Udgivet: (2016)
• Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
  af: Leiter, L. A., et al.
  Udgivet: (2018)
• Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial
  af: Ray, Kausik K., et al.
  Udgivet: (2018)
• Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan
  af: Teramoto, Tamio, et al.
  Udgivet: (2019)
• Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
  af: Bays, Harold E., et al.
  Udgivet: (2018)